BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).
| Peramivir Outpatient Flu(SEASONAL INFLUENZA / I.V.) |  |
| Peramivir Hospitalized Flu(ACUTE INFLUENZA / I.V.) |  |
| BCX4208(GOUT) |  |
